Krystal Biotech, Inc. (KRYS) Quick Ratio
- Quick ratio · latest quarter: Value 7.73×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 7.73× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $984.29M ÷ $127.40M ≈ 7.73× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 984.29M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 127.40M USD | Liabilities, Current |
| Cash and equivalents | 427.74M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 417.89M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 138.66M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 45.56M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $984.29M | $127.40M | $427.74M | $417.89M | $138.66M | $45.56M | 7.73× |
| 2026-03-31 | $950.43M | $107.80M | $501.31M | $322.09M | $127.02M | $42.65M | 8.82× |
| 2025-12-31 | $955.22M | $102.94M | $496.30M | $331.49M | $127.42M | $40.48M | 9.28× |
| 2025-09-30 | $860.70M | $91.27M | $392.60M | $338.46M | $129.63M | $37.63M | 9.43× |
| 2025-06-30 | $793.42M | $86.90M | $353.83M | $328.16M | $111.44M | $31.04M | 9.13× |
| 2025-03-31 | $720.11M | $79.49M | $308.77M | $308.08M | $103.26M | $29.94M | 9.06× |
| 2024-12-31 | $702.26M | $102.00M | $344.87M | $252.65M | $104.75M | $26.51M | 6.89× |
| 2024-09-30 | $685.62M | $89.53M | $373.97M | $214.36M | $97.30M | $18.58M | 7.66× |
| 2024-06-30 | $662.85M | $71.85M | $345.79M | $213.83M | $103.24M | $12.18M | 9.23× |
| 2024-03-31 | $584.73M | $47.59M | $359.01M | $179.25M | $46.47M | $11.04M | 12.29× |
| 2023-12-31 | $574.22M | $33.09M | $358.33M | $173.85M | $42.04M | $6.99M | 17.35× |
| 2023-09-30 | $571.38M | $27.58M | $373.24M | $188.83M | $9.32M | $5.28M | 20.72× |
| 2023-06-30 | (m) | $23.90M | $275.88M | $201.64M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $35.08M | $140.75M | $209.64M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $28.85M | $161.90M | $217.27M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $28.03M | $186.41M | $208.01M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $34.43M | $218.72M | $206.84M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $60.44M | $269.30M | $165.33M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $25.74M | $341.25M | $96.85M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $35.78M | $286.61M | $56.48M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $18.12M | $329.53M | $38.20M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $9.14M | $402.17M | $1.25M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $15.45M | $268.27M | $2.99M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $7.20M | $282.37M | $4.00M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $5.83M | $291.68M | $5.50M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $4.06M | $180.22M | $6.48M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $3.33M | $187.51M | $6.17M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $3.73M | $194.81M | $8.40M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $3.94M | $186.59M | $8.88M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.24M | $98.01M | $8.62M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.60M | $103.67M | $8.09M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $1.92M | $46.67M | $5.63M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $759.00K | $41.81M | $3.64M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $452.00K | $47.23M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $640.00K | $49.59M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.48M | $52.57M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $3.52M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $1.96M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $43.00K | $1.92M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $398.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |